You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Mass. Movers

Aegerion wins approval for its first drug

The Food and Drug Administration has approved Aegerion Pharmaceuticals’ request to market its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels. The condition is resistant to statins and other medications typically used to bring high cholesterol under control. The Cambridge biotech’s drug, Juxtapid, does carry a risk of liver toxicity, so it will come with a “black box” label — the FDA’s most serious warning level.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week